Skip to content

Sarah DeVos

  • PHD
  • In Vivo Scientist
  • Denali Therapeutics
  • 10h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 806CitationsNumber of citations received by Sarah's publications. Updated daily.

Other IDs

Co-authors (119)

  • Dustin Goncharoff
  • Ryan Sullivan
  • Elizabeth Tuck

Publications (5)

  • Synaptic tau seeding precedes tau pathology in human Alzheimer's disease brain

    • DeVos S
    • Corjuc B
    • Oakley D
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Characterization of TauC3 antibody and demonstration of its potential to block tau propagation

    • Nicholls S
    • Devos S
    • Commins C
    • et al.
    N/AReaders
    3Citations
    Get full text
  • Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies

    • Marquié M
    • Normandin M
    • Meltzer A
    • et al.
    N/AReaders
    33Citations
    Get full text
  • Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro

    • Nobuhara C
    • DeVos S
    • Commins C
    • et al.
    N/AReaders
    4Citations
    Get full text
  • Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

    • DeVos S
    • Miller R
    • Schoch K
    • et al.
    N/AReaders
    28Citations
    Get full text

Professional experience

In Vivo Scientist

Denali Therapeutics

March 2018 - Present

Postdoctoral Fellow

Massachusetts General Hospital

October 2014 - February 2018(3 years)

Education

PhD

Washington University in Saint Louis

August 2009 - June 2014(5 years)

BS

Central Michigan University

August 2000 - May 2005(5 years)